The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
August 29th 2025
The autoinjector, branded as Leqembi Iqlik, contains a 360 mg/1.8 mL dose administered over 15 seconds. It is expected to enhance Alzheimer treatment accessibility and offer cost savings for patients.
Encouraging Signs in Alzheimer Drug Development Despite Failures: Jeffrey Cummings, MD, ScD
December 3rd 2021The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed the positive trends within the Alzheimer drug development space. [WATCH TIME: 2 minutes]
The Substantial Costs Affiliated With Alzheimer Drug Development: Jeffrey Cummings, MD, ScD
December 2nd 2021The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed new data that highlights wasted expenditures from Alzheimer trials and the importance of understanding their impacts. [WATCH TIME: 3 minutes]
Key Takeaways From a Study of FUS in Early AD Dementia: Ali Rezai, MD
November 28th 2021The executive chair at the Rockefeller Neuroscience Institute at West Virginia University shed light on early data from a small sample of patients with early Alzheimer disease who underwent focused ultrasound treatment. [WATCH TIME: 5 minutes]
The Cost of Alzheimer Disease: Aducanumab’s Price and the Implications for CMS, Patients
November 24th 2021Aducanumab’s (Aduhelm; Biogen) $56,000 price point reflects the larger challenges of the United States’ insurance system and incites a cyclical series of events that have repercussions on cost of future therapies, state budgets, and legislative decisions.
AAN Issues Statement on Ethical Considerations for Aducanumab Use in Alzheimer Disease
November 23rd 2021The American Academy of Neurology’s statement touched on the roles played by the principles of beneficence, nonmaleficence, justice, and patient autonomy as it relates to the clinical use of the therapy for this patient population.
Incidence of Poststroke Dementia Remains Highly Prevalent
November 23rd 2021The risk of dementia was substantial and front-loaded following stroke, with the 1-year prevalence similar to the estimate for dementia at any time point. The findings indicate a need for greater engagement between stroke and dementia care.
Next Steps, Future Development of FUS Technology in Alzheimer Disease: Ali Rezai, MD
November 22nd 2021The executive chair of the Rockefeller Neuroscience Institute at West Virginia University discussed the potential of focused ultrasound for patients with AD, as well as key takeaways for clinicians from a recent study. [WATCH TIME: 5 minutes]
Evaluating Early Data on Focused Ultrasound for Patients With Alzheimer Disease
November 19th 2021Ali Rezai, MD, executive chair at the Rockefeller Neuroscience Institute at West Virginia University, outlined early data from a clinical trial utilizing focused ultrasound to open the blood-brain barrier in patients with mild AD.